Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Abstract Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Guadalupe Oñate, Marta Pratcorona, Ana Garrido, Alicia Artigas-Baleri, Alex Bataller, Mar Tormo, Montserrat Arnan, Susana Vives, Rosa Coll, Olga Salamero, Ferran Vall-Llovera, Antònia Sampol, Antoni Garcia, Marta Cervera, Sara Garcia Avila, Joan Bargay, Xavier Ortín, Josep F. Nomdedéu, Jordi Esteve, Jorge Sierra, Spanish Cooperative Group for the Study and Treatment of Acute Leukemias and Myelodysplasias (CETLAM)
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Publishing Group 2023-05-01
Serie:	Blood Cancer Journal
Accesso online:	https://doi.org/10.1038/s41408-023-00839-1
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!